1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

 
• By Tom Gallen

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.

Euro currency
• Source: Shutterstock

Acquiring in July a basket of six OTC brands from GlaxoSmithKline PLC has not sated Stada Arzneimittel AG’s appetite for further deals to grow its consumer health-focused Branded Products division.

The Germany-based firm told HBW Insight that it was “continuously evaluating OTC acquisitions” in line with its strategy of “rapid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Growing With Purpose – Inside Kenvue’s ‘Healthy Lives Mission’

 
• By David Ridley

HBW Insight speaks to Kenvue's global head of sustainability, Jennifer Duran, about the company's “Healthy Lives Mission,” including insights into how the firm is decarbonizing its supply chain, reducing the use of plastics and embedding sustainability into the design of new products.

Haleon Lowers Sales Guidance On Challenging US Retail Environment

 
• By Tom Gallen

A challenging US retail environment, with consumers cautious around spending, hit Haleon's North America sales in the first half of 2025. With the picture unlikely to improve in the second half, Haleon has lowered its sales guidance for the full year.

PharmaSGP Increases Sales Forecast Ahead Of Delisting

 
• By Tom Gallen

German consumer health player expects 2025 sales to be €10m higher than previously forecast after a better than predicted showing in the year-to-date.

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

 
• By Tom Gallen

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.

More from Business

PharmaSGP Increases Sales Forecast Ahead Of Delisting

 
• By Tom Gallen

German consumer health player expects 2025 sales to be €10m higher than previously forecast after a better than predicted showing in the year-to-date.

Change In P&G’s Helm Coming As Planning For Impact From Tariff Increases In Difficulty

 
• By Malcolm Spicer

Even as CEO Jon Moeller and lead board member Joe Jiminez as well as analysts state confidence the firm’s growth strategy will continue with the executive suite change, the impact of tariff policies could put a dent in its results.

Reckitt Leans On Europe As It Resets Mucinex In US

 
• By Tom Gallen

Decision to reformulate Mucinex sinus products without phenylephrine hits Reckitt's Q2 sales but the firm says it is preparing for upcoming cold & flu season with new marketing push.